EUCTR2012-001990-95-FR进行中（未招募）1 期
An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients must meet ALL of the following criteria:
- •1) Provide signed and dated written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA]).
- •2) Must have been enrolled in protocol TDU13583 (SG1/001/10).
- •3) Must have received a subretinal injection of SAR422459
- •4) Must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following would exclude patients from participation in the study:
- •1) Did not receive SAR422459 as part of the TDU13583 protocol
研究者
相似试验
进行中（未招募）
1 期
Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt’s Macular DegeneratioCTIS2024-513501-31-00Sanofi-Aventis Recherche & Developpement27
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyHereditary Transthyretin-Mediated Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2021-001427-40-CYIonis Pharmaceuticals, Inc.165
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyEUCTR2021-001427-40-FRIonis Pharmaceuticals, Inc.165
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyHereditary Transthyretin-Mediated Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2021-001427-40-ESIonis Pharmaceuticals, Inc.165
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyHereditary Transthyretin-Mediated Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2021-001427-40-SEIonis Pharmaceuticals, Inc.165